Northern Alliance Advanced Therapies Treatment Centre
The Northern Alliance Advanced Therapy Treatment Centre (NAATTC), formally established in March 2018, is a consortium of twenty industry, NHS and academic organisations led by Newcastle Hospitals and the Scottish National Blood Transfusion Service (SNBTS). The purpose of the centre is to develop the systems and infrastructure required to support the delivery of cell and gene therapies with the ultimate aim of increasing patient access to advanced therapy medicinal products (ATMPs) on a national level.
NAATTC’s vision is to increase patient access to advanced therapy medicinal products (ATMPs) regionally and nationally by growing a cost-effective clinical delivery pathway which meets the needs of the providers of advanced therapy products. The centre has a patient reach of circa 15 million spanning the North of England and Scotland and is working across two healthcare systems.
The centre will focus on all elements of the clinical delivery pathway from procurement of starting materials, near patient GMP, distribution and administration through to delivery of clinical trials and adoption and reimbursement across a range of advanced therapies and indications. This will entail the participation and collaboration of nurses, medical clinicians, hospital pharmacists, NHS managers, clinical commissioners and companies.
The NAATTC works across the north of England (Leeds and Newcastle upon Tyne) and Scotland.
The key objectives of the NAATTC are to:
- Identify all areas for improvement through gap analysis
- Design, devise and implement solutions in these areas
- Ensure that solutions are integrated across the clinical delivery pathway
- Roll out and disseminate best practice regionally and nationally.
The Centre will deliver its objectives over 36 months via six Work Packages;
- Manufacturing and Preparation
- Supply Chain
- Patient-Centred Advanced Therapy Delivery
- Infrastructure for Clinical Trials, Reimbursement and Adoption
- Wider Network Engagement
The Centre will develop best practice for safe and effective delivery of advanced therapies to patients. This will include robust and connected supply chains, tracking and tracing systems compliant with regulatory standards, patient follow up and data repositories and ultimately adoption and reimbursement based on clinical service delivery as well as product costs. A key component will be the use of informatics to achieve utility at scale in all elements of the clinical pathway, including product release.
The project will map Institutional Readiness Levels (IRLs; how far an organisation needs to adapt to embrace a new technology given pre-existing practices and infrastructure) for disruptive advanced therapies within the NAATTC and across the NHS and enable the therapies to achieve the highest IRLs within the time frame available. Close interaction between NAATTC, product and supply chain companies, regulators, health economists and healthcare commissioners will be essential to achieve this.
NAATTC’s innovative approach includes development with commercial partners of new and robust supply chains, tracking and capture processes, a harmonised Toolbox for procedures and processes, innovative training networks and novel ways to approach health and safety, including follow-up.
- Neil Watson, NAATTC Co-Director
- Marc Turner, NAATTC Co-Director
- Finn Willingham, NAATTC Operations Manager
- Michael Whitaker, Galen Biomed Ltd.
- Jim Shaw, Newcastle University
- Christopher Herbert, Leeds Teaching Hospitals NHS Foundation Trust
- Neil Bell, Autolus Therapeutics
- Andy Baker, University of Edinburgh
Governance – Terms of Reference
The NAATTC is overseen by governance structures including a Steering Board, made up of representatives from each Partner Organisation, an Executive Team as detailed above, and a Clinical Advisory Group and Industry Advisory Group. Further details of these structures and their Terms of Reference are available below.
NAATTC Steering Board:
NAATTC Executive Team:
NAATTC Clinical Advisory Group:
Dr Séamus O’Neill, Chief Executive Officer
Dr Nicola Wesley, Chief Operating Officer
Professor Anne Dickinson, Founder and Director
Dr John G Morris, Chief Executive Officer
Bill Shingleton, Alliances Manager
Neil Bell, Senior Vice President, Clinical Operations
Jim Faulkner, Senior Vice President, Product Delivery
Helen Delahaye, Project Manager
Karen Hodgkin, Chief Operating Officer
Julie De-Almeida, Head of Market Access UK & Ireland
Tom Chubb, Rare Disease Manager
Emma Banks, Chief Executive Officer
Jamie Pollard, Head of Software Development
NHS Greater Glasgow and Clyde
Dr David Irvine, Consultant Haematologist
Dr Samantha Carmichael, Lead Pharmacist – Clinical Trials/R&D
Melanie McColgan, General Manager, Specialist Oncology and Clinical Haematology
Leeds Teaching Hospitals NHS Trust
Dr Christopher Herbert, Director of Operations for Research and Innovation
Professor Gordon Cook, Professor of Haematology and Myeloma Studies
Dr Beki James, Consultant Paediatric Haematologist
Debbie Beirne, Manager and Deputy Director of the NIHR Leeds Clinical Research Facility
Michele Giroux, UK General Manager
NHS Blood and Transplant
Jon Smythe, Head of Cellular and Molecular Therapies
Professor Timothy Walsh, Head of Section/Lead of Edinburgh Critical Care Research Group, R&D Director – NHS Lothian
Neil Watson, Clinical Director of Pharmacy and Medicines Management and Co-Director of the NAATTC
Finn Willingham, Operations Manager, NAATTC
David Caulfield, Assistant Director of Pharmacy, QA
Anne Black, Regional QA Specialist/Lead for Newcastle Therapeutics
Janet Downie, Chief Executive Officer
Sue Bruce, Head of Commercial
Scottish National Blood Transfusion Service
Professor Marc Turner, Medical Director SNBTS and Co-Director of the NAATTC
Professor John Campbell, Associate Director – Tissues, Cells and Advanced Therapeutics
Ewan Morrison, Director of Pharmacy, National Services Scotland
Richard Bazell, Supervisor, Client Services
Christopher Stone, Supervisor, Client Services
Neil Ridley, Consultant Project Director
Luke Wilson, Lead Account Manager
Dr Matthew Lakelin, Chief Scientific Officer
Ben Innes, Project Manager
University of Edinburgh
Prof Stuart Forbes, Director, Scottish Centre for Regenerative Medicine (SCRM), WP3 Co-Lead, Clinical Advisory Group Clinician Scientist Lead
Prof Andy Baker, Scientific Advisor
Lisa Wotherspoon, Advanced Therapies Clinical Trial Coordinator
Simon Ellison, Cell and Gene Therapy Service Director